<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933543</url>
  </required_header>
  <id_info>
    <org_study_id>PC TA204/09</org_study_id>
    <nct_id>NCT00933543</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)</brief_title>
  <official_title>A Double Blinded, Prospective, Randomized, Stratified, Placebo-controlled, Multi-center Study of Photodynamic Therapy With VisonacTM Cream in Patients With Moderate to Severe Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from
      9 to 35 years old with AktiliteÂ® CL512. Patients was randomized to Visonac or vehicle cream
      without occlusion and red light(dose: 37J/cm2)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blinded, prospective, randomized, stratified, placebo-controlled, multi-center study
      in patients with moderate to severe acne vulgaris. Patients with facial severity grades 3 to
      4 on the Investigator's Global Assessment (IGA) scale will be included. Each patient will be
      classified according to age in the two age groups 9 to 12 years and 13 to 35 years and
      randomized to either Visonac or vehicle cream within each age group. All patients will
      receive 4 treatments 2 weeks apart (at week 0, 2 ,4 and 6 week). Efficacy evaluation will be
      done after each treatment and at 12 weeks after the first treatment. Safety evaluations will
      be performed at each treatment visit and at 12 weeks after the first treatment.

      Photographs of patients will be taken before and after treatment at first and last treatment
      visit, and at 12 weeks after first treatment.

      Blood samples will be drawn at 3 visits; pre-treatment visit, one week after first treatment
      and at one week after last treatment visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</measure>
    <time_frame>12 weeks after the first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules)</measure>
    <time_frame>12 weeks after the first treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Facial Non Inflammatory Lesion Count</measure>
    <time_frame>12 weeks after first treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</measure>
    <time_frame>12 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</measure>
    <time_frame>6 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</measure>
    <time_frame>12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Total Lesion Count</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Facial Total Lesion Count</measure>
    <time_frame>12 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Non-inflammatory Lesion Count</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Inflammatory Lesion Count From Baseline</measure>
    <time_frame>12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Facial Inflammatory Lesion Count</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Facial Non- Inflammatory Lesion Count</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Facial Total Lesion Count</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</measure>
    <time_frame>6 weeks after the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</measure>
    <time_frame>directly after first treatment</time_frame>
    <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</measure>
    <time_frame>directly after second treatment</time_frame>
    <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</measure>
    <time_frame>directly after third treatment</time_frame>
    <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</measure>
    <time_frame>directly after fourth treatment</time_frame>
    <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation</measure>
    <time_frame>at 12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Hyperpigmentation</measure>
    <time_frame>at 12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild or Moderate Scarring at End of Study</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Clear or Almost Clear Scarring at End of Study</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe and Very Severe Scarring at End of Study</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Hypopigmentation (Mild Moderate, Severe)</measure>
    <time_frame>at 12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Dryness (Mild)</measure>
    <time_frame>at 12 weeks after first treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Visonac cream with PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment, Light dose 37 J/cm2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream with PDT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment, Light dose 37 J/cm2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visonac PDT (MAL PDT)</intervention_name>
    <description>Cream application followed by illumination with red light.</description>
    <arm_group_label>Visonac cream with PDT</arm_group_label>
    <other_name>Visonac</other_name>
    <other_name>MAL PDT</other_name>
    <other_name>red light</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream (placebo)</intervention_name>
    <description>Cream application followed by illumination with red light.</description>
    <arm_group_label>Vehicle cream with PDT</arm_group_label>
    <other_name>Vehicle cream</other_name>
    <other_name>MAL PDT</other_name>
    <other_name>red light</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PDT</intervention_name>
    <description>Photodynamic Therapy - Light dose 37 J/cm2</description>
    <arm_group_label>Visonac cream with PDT</arm_group_label>
    <arm_group_label>Vehicle cream with PDT</arm_group_label>
    <other_name>Red light</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients, above 9 years of age with moderate to severe facial acne
             vulgaris (IGA score 3-4).

          -  Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent,
             or willing to use an adequate means of contraception including birth control pills, or
             barrier methods and spermicide for at least 14 days prior to T1. Patients using birth
             control pills must have used the same product and dose for at least 6 months and must
             agree to stay with the same product and dose for an additional 6 months.

          -  Fitzpatrick skin type I through VI.

          -  Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the
             face.

          -  Patients with 30 to 120 non-inflammatory lesions (open and closed comedones) on the
             face.

          -  Patients with no more than 2 nodular lesions on the face.

          -  Signed and verified informed consent form. For subjects under age of 18, an assent
             form in conjunction with an informed consent form, signed and verified by
             parent/guardian.

        Exclusion Criteria:

        Patients presenting with any of the following will not be included in the study:

          -  Patient is the investigator or any sub investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol.

          -  Patients unlikely to comply with the protocol, e.g., mental condition rendering the
             patient unable to understand the nature, scope, and possible consequences of the
             clinical study, uncooperative attitude or unlikelihood of completing the study (e.g.,
             drug or alcohol abuse).

          -  Female patients using oral contraceptives, that have not used the same product or dose
             within the last 6 months and do not agree to stay with the same product and dose for
             the duration of the study.

          -  Pregnancy

          -  Patients undergoing testosterone or any other systemic hormonal treatment.

          -  Patients using hormonal contraceptives solely for the control of acne.

          -  Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.

          -  Patients with porphyria.

          -  Patients with cutaneous photosensitivity.

          -  Participation in other clinical studies either concurrently or within the last 30
             days, before T1.

          -  Patients with a washout period for topical treatments e.g., topical BPOs, retinoids
             and antibiotics, for their acne of less than 14 days, before T1. Medicated cleansers
             may be used during the washout period and stopped before the treatment.

          -  Patients with a washout period for oral antibiotics for treatment of their acne of
             less than 1 month, before T1.

          -  Patients with a washout period for oral isotretinoin of less than 6 months, before T1.

          -  Patients with a beard or other facial hair that might interfere with study
             assessments.

          -  Patients with melanoma or dysplastic nevi in the treatment area.

          -  Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the
             last 30 days.

          -  Exposure to PDT within 12 weeks before T1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence F. Eichenfield, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Specialists of San Diego / Rady Children's Hospital San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Specialists of San Diego / Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Institute of DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison Skin &amp; Research, Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor, Ontario N8W 5L7</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INNOVADERM Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique</name>
      <address>
        <city>QuÃ©bec</city>
        <state>Quebec</state>
        <zip>2880</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>October 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Moderate to severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from September-December 2009. Dermatology clinics, with pediatric patients</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Visonac Cream With PDT</title>
          <description>Active treatment, Light dose 37 J/cm2.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Visonac Cream With PDT</title>
          <description>Active treatment, Light dose 37 J/cm2.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with mild and moderate hyperpigmentation</title>
          <units>number of patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator Global Assessment (IGA) Score</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IGA 3 (Moderate acne)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA 4 (Severe acne)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin type</title>
          <description>I: White; very fair; red or blond hair; blue eyes; freckles Always burns, never tans II: White; fair; red or blond hair; blue, hazel or green eyes Usually burns, tans with difficulty III: Cream white; fair with any eye or hair color; very common Sometimes mild burn, gradually tans IV: Brown; typical Mediterranean Caucasian skin Rarely burns, tans with ease V: Dark brown; Middle Eastern skin types Very rarely burns, tans very easily VI: Black Never burns, tans very easily</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Skin type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scarring</title>
          <description>The investigator assess the scarring using a scale called SCAR-S. Clear 0: No visible scars from acne. Almost clear 1: Hardly visible scars from 2.5 meters away. Mild 2: Easily recognizable, less than Â½ the affected area (eg. face, back or chest) involved.
Moderate 3: More than Â½ affected area (eg. face, back or chest) involved. Severe 4: Entire area involved. Very severe 5: Entire area with prominent atrophic or hypertrophic scars.</description>
          <units>number of patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patients with no scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with almost clear scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with mild scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with moderate scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with severe scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with very severe scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with dryness</title>
          <description>The investigator assess the dryness using a scale from 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe).</description>
          <units>Number of patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild dryness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</title>
        <time_frame>12 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</title>
          <population>ITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" lower_limit="1.53" upper_limit="16.99"/>
                    <measurement group_id="O2" value="1.89" lower_limit="0.00" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Ï (Vehicle PDT) = Ï (MAL PDT) versus HA: Ï (Vehicle PDT) â  Ï (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0703</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test stratified by center. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>63.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</title>
          <population>ITT</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.4" spread="30.85"/>
                    <measurement group_id="O2" value="-20.3" spread="38.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules)</title>
        <time_frame>12 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count (Nodules, Papules, and Pustules)</title>
          <population>ITT</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="17.94"/>
                    <measurement group_id="O2" value="-13.8" spread="23.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Ï (Vehicle PDT) = Ï (MAL PDT) versus HA: Ï (Vehicle PDT) â  Ï (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2969</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model, including center and baseline lesion count as a covariates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.35</ci_lower_limit>
            <ci_upper_limit>3.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Facial Non Inflammatory Lesion Count</title>
        <time_frame>12 weeks after first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Non Inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="26.54"/>
                    <measurement group_id="O2" value="-17.1" spread="25.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: Ï (Vehicle PDT) = Ï (MAL PDT) versus HA: Ï (Vehicle PDT) â  Ï (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8913</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model, including center and baseline lesion count as a covariates</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.09</ci_lower_limit>
            <ci_upper_limit>10.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</title>
        <time_frame>12 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Inflammatory (Nodules, Papules, and Pustules)Lesion Count</title>
          <population>ITT</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.1" spread="39.34"/>
                    <measurement group_id="O2" value="-27.5" spread="44.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</title>
        <time_frame>6 weeks after first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3" spread="39.72"/>
                    <measurement group_id="O2" value="-15.8" spread="47.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</title>
        <time_frame>12 weeks after first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Non Inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.0" spread="52.23"/>
                    <measurement group_id="O2" value="-24.4" spread="37.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Total Lesion Count</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Total Lesion Count</title>
          <population>ITT</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="27.72"/>
                    <measurement group_id="O2" value="-18.0" spread="35.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Facial Total Lesion Count</title>
        <time_frame>12 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Facial Total Lesion Count</title>
          <population>ITT</population>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.8" spread="36.04"/>
                    <measurement group_id="O2" value="-26.8" spread="29.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Non-inflammatory Lesion Count</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Non-inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Inflammatory Lesion Count From Baseline</title>
        <time_frame>12 weeks after first treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Reduction of at Least 50% From Baseline in Facial Inflammatory Lesion Count From Baseline</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="9.0"/>
                    <measurement group_id="O2" value="-10.8" spread="22.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Facial Non- Inflammatory Lesion Count</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Non- Inflammatory Lesion Count</title>
          <population>ITT</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="21.41"/>
                    <measurement group_id="O2" value="11.3" spread="28.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Facial Total Lesion Count</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Facial Total Lesion Count</title>
          <population>ITT</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.2" spread="26.19"/>
                    <measurement group_id="O2" value="-20.6" spread="36.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</title>
        <time_frame>6 weeks after the first treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an Improvement of at Least 2 Grades From the Baseline Score.</title>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
        <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
        <time_frame>directly after first treatment</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
          <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
          <population>Safety population</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.2" lower_limit="0.0" upper_limit="9.8"/>
                    <measurement group_id="O2" value="0.28" spread="0.64" lower_limit="0.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
        <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
        <time_frame>directly after second treatment</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
          <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
          <population>Safety population</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.0" upper_limit="8.5"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
        <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
        <time_frame>directly after third treatment</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
          <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
          <population>Safety population</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="0.0" upper_limit="8.1"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
        <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
        <time_frame>directly after fourth treatment</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Assessed Using a Visual Analogue Scale From 0 to 10, Where 0 Indicates no Pain and 10 Indicates Worst Pain Imaginable</title>
          <description>Facial pain was assessed on a visual analogue scale ranging from 0-10cm.</description>
          <population>Safety population</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.0" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation</title>
        <time_frame>at 12 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation</title>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Hyperpigmentation</title>
        <time_frame>at 12 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Hyperpigmentation</title>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild or Moderate Scarring at End of Study</title>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild or Moderate Scarring at End of Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Clear or Almost Clear Scarring at End of Study</title>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Clear or Almost Clear Scarring at End of Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe and Very Severe Scarring at End of Study</title>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe and Very Severe Scarring at End of Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Hypopigmentation (Mild Moderate, Severe)</title>
        <time_frame>at 12 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Hypopigmentation (Mild Moderate, Severe)</title>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Dryness (Mild)</title>
        <time_frame>at 12 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Visonac Cream With PDT</title>
            <description>Active treatment, Light dose 37 J/cm2.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream With PDT</title>
            <description>Placebo treatment, Light dose 37 J/cm2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Dryness (Mild)</title>
          <population>Safety</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Visonac Cream With PDT</title>
          <description>Active treatment, Light dose 37 J/cm2.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cream With PDT</title>
          <description>Placebo treatment, Light dose 37 J/cm2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.8</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraestehesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project director Per Fuglerud</name_or_title>
      <organization>Photocure</organization>
      <phone>+47 22 06 16 54</phone>
      <email>pf@photocure.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

